References
- Lipinski C. (2002). Poor aqueous solubility, an industry wide problem in drug discovery. Am Pharm Rev, 5:82–85.
- Rasenack N, Müller BW. (2002). Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm Res, 19:1894–1900.
- Müler RH, Peters K. (1998). Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique. Int J Pharm, 160:229–237.
- Rabinow BE. (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov, 3:785–796.
- Matteucci ME, Hotze MA, Johnston KP, Williams RO 3rd. (2006). Drug nanoparticles by antisolvent precipitation: Mixing energy versus surfactant stabilization. Langmuir, 22:8951–8959.
- Chen X, Matteucci ME, Lo CY, Johnston KP, Williams RO 3rd. (2009). Flocculation of polymer stabilized nanocrystal suspensions to produce redispersible powders. Drug Dev Ind Pharm, 35:283–296.
- Yassin AE, Alanazi FK, El-Badry M, Alsarra IA, Barakat NS, Alanazi FK. (2009). Preparation and characterization of spironolactone-loaded gelucire microparticles using spray-drying technique. Drug Dev Ind Pharm, 35:297–304.
- Pouleur HG. (1997). Clinical overview of irbesartan: A new angiotensin II receptor antagonist. Am J Hypertens, 10:318S–324S.
- Brunner HR. (1997). The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. Am J Hypertens, 10:311S–317S.
- Chawla G, Bansal AK. (2008). Improved dissolution of a poorly water soluble drug in solid dispersions with polymeric and non-polymeric hydrophilic additives. Acta Pharm, 58:257–274.
- Wang Z, Huang Q, Wang J, Shao L, Chen J. (2008). Preparation of amorphous micronized irbesartan by an antisolvent precipitation method. J Beijing Univ Chem Tech, 35:69–73.
- Hirlekar R, Kadam V. (2009). Preformulation study of the inclusion complex irbesartan-β-cyclodextrin. AAPS Pharmscitech, 10:276–281.
- Hancock BC, Parks M. (2000). What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res, 17:397–404.
- Pan X, Julian T, Augsburger L. (2008). Increasing the dissolution rate of a low-solubility drug through a crystalline-amorphous transition: A case study with indomethacin [correction of indomethicin]. Drug Dev Ind Pharm, 34:221–231.
- de Waard H, Hinrichs WL, Frijlink HW. (2008). A novel bottom-up process to produce drug nanocrystals: Controlled crystallization during freeze-drying. J Control Release, 128:179–183.
- Hancock BC, Zografi G. (1994). The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids. Pharm Res, 11:471–477.
- Chan HK, Chew NY. (2003). Novel alternative methods for the delivery of drugs for the treatment of asthma. Adv Drug Deliv Rev, 55:793–805.
- Caron A, Chantreux D, Bouloumie C. (1997). Process for the preparation of a tetrazole derivative in two crystalline forms and novel the crystalline forms thereof. US patent no. 5629331.
- Reddy RB, Sudhakar S. (2003). Amorphous form of 2-n-butyl-3-((2-(1h-tetrazol-5-yl) (1,1′-biphenyl)-4-yl) methyl)-1,3-diazaspiro (4,4′) non-1-en-4-one. World patent no. 03050110.
- Parthasaradhi RB, Rathnakar RK, Raji RR, Ramakrishna RM. (2004). A novel crystalline form of irbesartan. World patent no. 2004089938.
- Ziller KH, Rupprecht HH. (1990). Control of crystal growth in drug suspensions. Part II: Influence of polymers on dissolution and crystallization during temperature cycling. Pharm Ind, 52:1017–1022.
- Muhammad SA, Langrish T, Tang P, Adi H, Chan HK, Kazarian SG et al. (2010). A novel method for the production of crystalline micronised particles. Int J Pharm, 388:114–122.
- Lu J, Wang X, Ching C. (2003). Effect of additives on the crystallization of lysozyme and chymotrypsinogen A. Crystal Growth & Design, 3:83–87.
- Zhang ZB, Shen ZG, Wang JX, Zhang HX, Zhao H, Chen JF et al. (2009). Micronization of silybin by the emulsion solvent diffusion method. Int J Pharm, 376:116–122.
- Williams ML, Landel RF, Ferry JD. (1955). The temperature dependence of relaxation mechanisms in amorphous polymers and other glass-forming liquids. J Am Chem Soc, 77:3701–3707.
- Lang R, Winter G, Vogt L, Zurcher A, Dorigo B, Schimmele B. (2009). Rational design of a stable, freeze-dried virus-like particle-based vaccine formulation. Drug Dev Ind Pharm, 35:83–97.